gene_symbol
ERBB2
hgnc_id
HGNC:3430
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
The trastuzumab ADC binds HER2 on tumor cells, is internalized, and releases a camptothecin-derived payload (rezetecan) that inhibits Topoisomerase I, causing DNA damage, replication arrest, and apoptosis of HER2-expressing cells.
enzyme_product
On
epitope
On
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
cell-surface receptor tyrosine kinase targeted by trastuzumab moiety
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06123494
disease_id_num_tar_ref
745
drug_id_num_tar_ref
2064